PGEN News and Press, Precigen Inc. From 03/01/22

Precigen press release (NASDAQ:PGEN): Q4 GAAP EPS of -$0.13 beats by $0.01. Revenue of $24.22M (+25.3% Y/Y) beats by $1.98M. Cash, cash equivalents, and short-term and long-term investments totaled $163.7 million as of December 31, 2021 For further details see: Precigen GAAP EPS of -$0....

Precigen Reports Fourth Quarter and Full Year 2021 Financial Results - 2021 clinical milestone objectives successfully accomplished - - Positive clinical data presented across three platforms - UltraCAR-T®, AdenoVerse™, ActoBiotics™ - and five clinical pro...

Precigen Provides Pipeline and Corporate Updates at the 40th Annual J.P. Morgan Healthcare Conference - Company accomplished clinical milestones set for 2021 - - Phase 2 trial planned for PRGN-2009 in combination with an anti-PD-1 checkpoint inhibitor in advanced human papil...

Precigen to Present at the 40th Annual J.P. Morgan Healthcare Conference - Management will also participate in a panel discussion at the H.C. Wainwright BioConnect 2022 Conference - PR Newswire GERMANTOWN, Md. , Jan. 5, 2022 /PRNewswire/ -- Prec...

Precigen's (NASDAQ:PGEN) acute myeloid leukemia candidate PRGN-3006 UltraCAR-T demonstrated an objective response rate of 50% based on six patients. In the lymphodeletion cohort, there were two complete responses at the two lowest dose levels. In the same cohort, stable disease for more ...

Precigen Announces Positive Interim Phase 1 Data for PRGN-3006 UltraCAR-T® in Relapsed or Refractory Acute Myeloid Leukemia - A single administration of UltraCAR-T cells following overnight manufacturing demonstrated robust expansion and persistence in blood and bone marrow...

Precigen (PGEN +10.6%) is up 8.89% today after some insider buying. In SEC filings, the company disclosed that Director Randal J. Kirk bought 1M shares at $3.52 - $3.75 worth ~ $3.6M. For further details see: Precigen gains 9% as Director buy 1M shares

Precigen to Present at the Stifel 2021 Virtual Healthcare Conference PR Newswire GERMANTOWN, Md. , Nov. 10, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapi...

Precigen Achieves Significant Clinical Progress for UltraCAR-T® and AdenoVerse™ Therapies - 50% (3 out of 6) objective response rate (ORR) in relapsed or refractory (r/r) acute myeloid leukemia (AML) patients treated with PRGN-3006 at the two lowest dose levels (a si...

Read the full article here. For further details see: Wall Street Breakfast: The Week Ahead (Podcast)